On August 1, Professor Chen Tao, director of Immunotherapy Department of Cancer Center of Excellence of Guangzhou R&F Hospital, and his delegation visited Shenzhen Cell Valley for exchange. Shi Yuanyuan, chairman of our company, Wang Jianxun, chief scientist, Xiang Hua, Deputy General manager, Zhao Lijun, Director of Research and Development Department, Wang Lu, director of General Office and other warmly received them.
 


Professor Chen Tao and his delegation, accompanied by Minister Zhao Lijun, visited the Smart exhibition Hall and had a preliminary understanding of the strategic positioning, founder team, development history and core technology patent overview of Shenzhen Cell Valley. Subsequently, through field visits to our GMP level production research and development laboratory and quality management laboratory, we deeply discussed our company's unique competitive advantages in the core technology - retroviral vector preparation and cell product production technology, and highly recognized the strict monitoring system of traceability of the whole process implemented in quality management.
 

 

At the symposium, Minister Zhao Lijun gave a detailed introduction to the core technical team, recent scientific research achievements and clinical application cases of Shenzhen Cell Valley. Among them, Chairman Shi Yuanyuan introduced that Dr. Zhao Lijun, as the director of the R&D department of Shenzhen Cell Valley, has recently published high-level academic papers on bisspecific CAR-T in cooperation with the Deep Research Institute of Peking University. The novel bisspecific CD19/CD22 LoopCAR-T technology represented by this achievement has been successfully prepared by Shenzhen Cell Valley and put into clinical application. At present, the technology has been completed in the Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital) on the clinical treatment of 4 patients with B-cell malignant tumor, and achieved remarkable therapeutic effect. In addition, Shenzhen Cell Valley has established close cooperation with a number of medical institutions, and successfully carried out a number of cases of novel targeted CAR T cell therapy based on retroviral vector preparation, including CD19, BCMA, CD19/CD22, CD7, CD38, etc., all of which have shown good effectiveness and safety, bringing new hope for patients.

Professor Chen Tao said that Guangzhou R&F Hospital Cancer Center of Excellence based on the construction of international top cancer diagnosis and treatment institutions and domestic first-class cancer specialty standards, the introduction of Medpoint international medical management and operation experience, and cooperation with international medical centers to build a cancer prevention and control center. The team is composed of famous experts from major cancer centers and specialties in China, including international and domestic experts in the diagnosis, treatment and nursing of cancer subspecialties. The purpose of this visit is to conduct in-depth exchanges with Shenzhen Cell Valley therapeutic product R&D team, jointly explore the latest technological developments in cell target cell therapy, and accelerate the transformation of scientific research results into clinical applications through deep cooperation between platforms.

In addition, the two sides also conducted in-depth discussions on possible future cooperation models, and both sides agreed that by building an open and shared cooperation platform and integrating the superior resources of the two sides, the research and development efficiency and innovation ability of cell therapy technology can be greatly improved, and greater contributions to the cause of medical health.